Overview

Study of STG-001 in Subjects With Stargardt Disease

Status:
Completed

Trial end date:
2021-04-24

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter study in subjects with Stargardt disease, comparing 2 doses of STG-001 with regard to safety, pharmacokinetics and pharmacodynamics.

Phase:

Phase 2

Details

Lead Sponsor:

Stargazer Pharmaceuticals, Inc.